

1 Global lymphatic filariasis post-validation surveillance 2 activities in 2024: A systematic review protocol

3 Holly Jian ^{1,*,¶}, Harriet Lawford ^{1,¶}, Angus McLure ², Colleen Lau ¹, Adam Craig ¹

4 ¹ Centre for Clinical Research, Faculty of Medicine, The University of Queensland, Brisbane, Australia

5 ² National Centre for Epidemiology and Population Health, Australian National University, Canberra, Australia

6 * Corresponding author

7 Email: h.jian@uq.edu.au (A1)

8 Address: UQ Centre for Clinical Research, Building 71/918, Royal Brisbane & Women's Hospital Campus, Herston,
9 QLD, 4029

10 ¶ These authors contributed equally to this work.

11 Abstract

12 **Introduction:** Lymphatic filariasis (LF) is a neglected tropical disease caused by infection with parasitic worms, spread by
13 mosquitoes. In countries where LF is validated as eliminated as a public health problem by the World Health Organization
14 (WHO), post-validation surveillance (PVS) is required to ensure recrudescence has not occurred and verify the sustained
15 elimination of transmission. However, it is unclear what PVS strategies should be applied, how PVS strategies should be
16 tailored to meet country capacity and need, and whether currently used approaches align with upcoming WHO guidelines.

17 **Objectives:** This study will aim to review available evidence on PVS implementation in countries previously endemic for
18 LF; examine barriers and facilitators to PVS implementation; critique alignment in PVS activities with international
19 guidelines; and identify knowledge gaps in PVS implementation that may be addressed through further research.

20 **Methods:** We will search four databases (PubMed, Scopus, Embase and Web of Science) for peer-reviewed literature and the
21 WHO Institutional Repository for Information Sharing (IRIS) database for grey literature. Documents published between
22 January 1, 2007 and November 5, 2024 will be included. Two reviewers will independently screen studies based on a priori
23 inclusion and exclusion criteria. The quality of included studies will be assessed using the Joanna Briggs Institute Critical
24 Appraisal Checklist, and deductive content analysis will be conducted to synthesise data. The study will also examine
25 alignment with upcoming WHO PVS guidelines.

26 **Conclusion:** This review will systematically collate and analyse available literature on PVS of LF, which, to our knowledge,
27 has not yet been conducted. Our study will synthesise knowledge in this field and provide an evidence base which may be
28 used to guide the design of future PVS strategies.

29 This protocol has been registered in PROSPERO (registration ID: [CRD42024618436](https://www.crd.york.ac.uk/PROSPERO/registration/CRD42024618436)).

30 Introduction

31 Lymphatic filariasis (LF) is a neglected tropical disease caused by infection from three species of thread-like parasitic worms:
32 *Wuchereria bancrofti*, *Brugia malayi* and *B. timori*. *W. bancrofti* causes 90% of infections worldwide and is spread primarily
33 by *Aedes*, *Anopheles* and *Culex* genus mosquitoes. The typical vector for *Brugia* spp. filariasis are mosquito species in the
34 genera *Mansonia* and *Aedes* [1, 2].

35 Lymphatic filariasis is endemic in 72 countries worldwide [3]. Chronic infection can lead to lymphoedema (tissue swelling)
36 or elephantiasis (skin and tissue thickening) of limbs and hydrocoele (scrotal swelling) [4]. The resulting disfigurement and
37 disability can lead to physical impairment and social stigmatisation, and individuals are often ostracised and lose employment
38 [5]. In 1998, prior to the establishment of the Global Programme for the Elimination of Lymphatic Filariasis (GPELF),
39 chronic LF had an estimated disability-adjusted life-years (DALY) burden of 5.25 million and an estimated economic burden
40 of USD 2.5 billion annually, largely due to disability and loss of employment. In 2019, the burden was reported to have more
41 than halved with burden being estimated at 1.63 million DALYs [6, 7].

42 The GPELF was launched in 1998 and is one of the largest global public health interventions ever mounted. The programme
43 aims to eliminate LF as a public health problem through multiple rounds of mass drug administration (MDA), as well as
44 managing morbidity and preventing disability among those already infected [8, 9]. Regional and national programmes were
45 later established, recognising that diverse epidemiological profiles and contextual factors required tailored strategies for
46 successful implementation. These include the establishment of the Pacific Programme for the Elimination of Lymphatic
47 Filariasis (PacELF) in 1999 [1], the South-East Asia regional programme to eliminate lymphatic filariasis in 2000 [10], and
48 various national programmes across the World Health Organization (WHO) Regional Office for Africa [11].

49 The elimination of LF as a public health problem is defined by WHO as reducing prevalence of infection to below defined
50 target thresholds [12]. Once targets have been reached, countries are validated by WHO as having eliminated LF as a public
51 health problem. The validation process requires the preparation and submission of a dossier proving the sustained reduction
52 of LF prevalence nationally. This is based on initial surveys in high-risk sentinel sites that show the prevalence of infection is
53 below the target threshold in populations aged over five years of age, known as pre-transmission assessment surveys (pre-
54 TAS). These are then followed by a transmission assessment survey (TAS1) showing that the prevalence of infection is
55 below the target threshold in a sample of children under seven years. After MDA stops, subsequent surveys must show
56 sustained low prevalence of infection in children aged under seven for two years (TAS2) and four years (TAS3) [13]. The
57 thresholds used in these surveys are defined as an antigen or antibody prevalence level at which further transmission is
58 unlikely, even in the absence of further rounds of MDA or other interventions. Thresholds vary depending on the
59 predominant filarial species and vector in each country [14].

60 Following the validation of elimination of LF as a public health problem, WHO guidelines require that post-validation
61 surveillance (PVS) be conducted [13]. PVS is ongoing surveillance following elimination, with the aim of ensuring

62 recrudescence has not occurred. A secondary aim of PVS is to detect and provide care for persons affected by lymphoedema
63 and hydrocoele [15].

64 Provisional guidelines suggest that PVS should be continued for at least ten years after validation to monitor for
65 recrudescence. Evidence emerging from the Pacific islands and Sri Lanka indicates that, even after the criteria for elimination
66 as a public health problem have been met, local LF transmission can continue. Where appropriate PVS is not implemented,
67 continued transmission may result in re-establishment of transmission and threatening the successes of many years of MDA
68 [16–18].

69 The WHO *Road Map for Neglected Tropical Diseases 2021–2030* aim that all 72 LF-endemic countries will no longer
70 require MDA and will be implementing PVS or post-MDA surveillance by 2030. Additionally, the Road Map aims for at
71 least 80% of LF endemic countries (58/72) to have been validated for the elimination of LF as a public health problem by
72 2030 [19].

73 China, in 2007, became the first country to be validated by WHO as having eliminated LF as a public health problem. Since
74 then (up to November 2024), 21 other countries have met the epidemiological threshold, prepared and submitted a dossier
75 and been validated by WHO as having eliminated LF. Twelve others have reduced prevalence levels to below the
76 epidemiological threshold for elimination but are still completing TAS. The disease remains endemic in 39 countries that still
77 require MDA [3, 8, 20].

78 **Figure 1: Distribution of lymphatic filariasis and status of preventative chemotherapy (PC) in endemic countries, 2024**

79 At the time of writing (November 2024), WHO guidelines for PVS had been drafted and presented at international meetings
80 but had not officially been released. Based on the content presented, we expect that the guidelines will recommend countries
81 implement two of the following four PVS strategies: health-facility based screening; integration of PVS into existing
82 population surveys; targeted LF surveillance of high-risk groups; and molecular xenomonitoring [16].

83 The implementation of effective PVS requires a robust understanding of countries' unique geographic and epidemiological
84 profile, operational context, and challenges and enablers to PVS implementation. Importantly, experiences in one country
85 may inform, but should not dictate, approaches taken by another; context, capacity, and need will inevitably differ. Given
86 this, the aims of this systematic review are to identify and synthesise evidence on PVS activities globally, establishing an
87 evidence base on which future guidelines and strategies may draw. Specifically, the objectives of this review are to:

- 88 1. Profile post-validation or post-elimination surveillance activities, or lack thereof, in countries previously endemic
89 for LF that have been validated by the WHO as having eliminated LF
- 90 2. Examine barriers and facilitators to the implementation of PVS strategies, and how these vary by context.
- 91 3. Identify alignment of PVS activities with upcoming WHO guidelines
- 92 4. Identify knowledge gaps in PVS implementation methods that may be addressed through further operational
93 research.

94 **Methods**

95 This study will be conducted in line with the PRISMA guidelines.

96 **Research question**

97 The Population, Intervention/Exposure, Comparator, Outcome and Time (PICOT) framework was used to develop research
98 questions. As this review aims to scope and critique the PVS strategies being employed across several countries, we
99 determined that identifying a Comparator was not required.

100 **Table 1: PICOT components**

PICOT	
Population	Countries that have been validated by WHO as having eliminated LF: Bangladesh, Cambodia, Cook Islands, Egypt, Kiribati, Lao People's Demographic Republic, Malawi, Maldives, Marshall Islands, Niue, Palau, Sri Lanka, Thailand, Togo, Tonga, Vanuatu, Vietnam, Yemen, Wallis & Futuna, Brazil and Timor-Leste
Exposure or intervention	Lymphatic filariasis
Outcome	Post-validation or post-elimination surveillance
Comparator	N/A
Time	2007–2024 (inclusive)

101

102 **Identifying studies**

103 **Information sources and search strategy**

104 PubMed, Scopus, Embase and Web of Science will be used to search for peer-reviewed journal articles; the WHO

105 Institutional Repository for Information Sharing (IRIS) database was used to search for grey literature reports published by

106 WHO.

107 A search strategy using MeSH search terms, free text key words, and Boolean operators has been developed. Table 2 outlines

108 the search strategy that will be used. Appendix A presents the search terms used across each literature database.

109 **Table 2: Search terms by PICOT**

PICOT	Search Term	Add with
Population	"Bangladesh"[Mesh] OR Bangladesh* OR "Cambodia"[Mesh] OR Cambodia* OR Cook Island* OR "Egypt"[Mesh] OR Egypt* OR Kiribati* OR "I-Kiribati" OR "Laos"[Mesh] OR Laos OR "Malawi"[Mesh] OR Malawi* OR Maldiv* OR Marshall Island* OR Niue* OR Palau* OR "Sri Lanka"[Mesh] OR Sri Lanka* OR "Thailand"[Mesh] OR Thai* OR "Togo"[Mesh] OR Togo* OR Tonga* OR Vanuatu* OR "Vietnam"[Mesh] OR Vietnam* OR "Yemen"[Mesh] OR Yemen* OR "Wallis and Futuna" OR Wallis* OR Futuna* OR "Brazil"[Mesh] OR Brazil* OR "Timor-Leste"[Mesh] OR Timor*	AND
Intervention or exposure	"Elephantiasis, Filarial"[Mesh] OR "lymphatic filariasis" OR elephantias* OR filaria* OR "filarial elephantiasis" OR filarial lympho*dema OR "Wuchereria bancrofti" OR "Brugia malayi" OR "Brugia timori" OR Bancrofti* OR Brugia*	AND
	"Sentinel Surveillance"[Mesh] OR "sentinel surveillance" OR "Public Health Surveillance" [Mesh] OR "public health surveillance" OR "Population Surveillance"[Mesh] OR "population surveillance" OR "Monitoring,	AND

	Physiologic"[Mesh] OR "physiologic monitoring" OR "Epidemiological Monitoring"[Mesh] OR "Mass Screening"[Mesh] OR "mass screening"	
Outcome	"post-elimination" OR "post-validation" OR elimination OR validation	
Comparator	N/A	
Time	2007–2024 (inclusive)	

110

111 **Data management, study screening and selection**

112 Data management, study screening and selection will be performed with the aid of Covidence software

113 (<https://www.covidence.org/>).

114 Search results from the selected databases will be imported into Covidence, and duplicates removed.

115 Papers will be included if they:

- 116 • Describe PVS activities conducted between 2007–24 (inclusive) in a country or territory that has been validated by
- 117 WHO as having eliminated LF.
- 118 • Were original research, activity reports, protocols or WHO grey literature describing population-level surveillance
- 119 • Were written in English, Portuguese, French or Chinese.
- 120 • Were published between January 2007 and November 2024.

121 Papers will be excluded if they:

- 122 • Describe only surveillance activities that occurred pre-validation by WHO of elimination of LF.
- 123 • Do not describe studies in a LF-eliminated country or territory.
- 124 • Do not describe surveillance activities (including diagnostic validation and modelling studies, letters, editorials and
- 125 commentary articles).

126 Two researchers (HJ and HL) will independently screen the selected records using the above criteria by title and abstract.

127 Where mismatches in screening assessments occur, HJ and HL will discuss and aim to find consensus; if required, a third

128 reviewer (AC) will be consulted. If resolution cannot be found, a conservative approach will be taken and the article included

129 in the review. Following title and abstract screening, HJ will conduct full-text screening.

130 Screening decisions will be documented using a PRISMA flow diagram.

131 Data extraction

132 Data will be extracted by one researcher (HJ) using a Covidence data extraction form developed by the research team. Table
133 3 outlines the fields for which data will be extracted.

134 **Table 3: Information to be extracted**

Category	Item
Publication information	<ul style="list-style-type: none">• Year of publication• Country• Funding sources
Epidemiology of LF	<ul style="list-style-type: none">• Type of LF (<i>Wuchereria bancrofti</i>, <i>Brugia malayi</i>, <i>Brugia timori</i>)• Species of LF vector (<i>Culex</i>, <i>Aedes</i>, <i>Mansonia</i>)• Co-endemic diseases• Year in which LF was validated as eliminated• Prevalence of LF during<ol style="list-style-type: none">1. Endemic phase2. Post-MDA surveillance3. Post-validation surveillance• High-risk or priority populations during elimination (e.g. historic hot spots)
Post-validation surveillance activities	<ul style="list-style-type: none">• Years in which PVS activities were conducted• Type of surveillance activities conducted• Alignment with WHO guidelines (activity type, frequency)• Sampling design (targeted, clustered, population-representative)• Surveillance type (active, passive, sentinel)• Type of testing (human antigen, antibody, and microfilaria; molecular xenomonitoring of mosquitoes)• Other activities (including risk reduction and vector management)

Operational challenges or opportunities	<ul style="list-style-type: none">• Funding sources• Staffing• Resources• Technical capacity• Social, political or economic drivers
---	---

135

136 **Analysis**

137 A narrative synthesis of PVS activities will be conducted. This will aim to describe PVS activities by country, their alignment
138 with WHO guidelines, and specific challenges or enablers to their implementation. The review will examine differences or
139 similarities between countries and aim to identify learnings that can be translated across settings.

140 A deductive content analysis approach will be employed, using the methodology outlined by Elo and Kyngas (2008). A
141 deductive approach was selected due to its applicability in testing existing models in different contexts; in this case, this
142 approach will be used to examine the application of PVS strategies recommended by WHO across countries endemic for LF.
143 Deductive coding will be conducted using a constrained categorisation matrix based on Table 3, with a focus on identifying
144 emerging themes relating to alignment with WHO guidelines, operational challenges and opportunities [21].

145 **Ethical considerations and dissemination of results**

146 This review does not require ethical approval as it will use published data only. This study will be internally funded by The
147 University of Queensland.

148 We anticipate publishing our results in a peer-reviewed publication. Additionally, we expect that the work will be presented
149 at relevant international conferences and global and national LF elimination-related meetings.

150 **Quality assessment**

151 Two reviewers will independently assess the quality of selected studies based on the eight criteria as described in the Joanna
152 Briggs Institute critical appraisal checklist for use in reviews of cross-sectional studies (Appendix C). Each criterion will be

153 given a score of 1 if a criterion is met or 0 if a criterion is not met, with a maximum possible score of 8. Studies scoring from
154 0 to 4 will be considered low quality, from 5 to 7 moderate quality, and from 8 to 9 high quality [22].

155 **Discussion**

156 Our systematic review will synthesise the literature on PVS activities in countries that have been validated as having
157 eliminated LF as a public health problem. It is anticipated that this review will bring together evidence on challenges and
158 enablers in the implementation of these activities, as well as identify gaps that may require further operational research.
159 Additionally, we anticipate that the review will assess whether what has been conducted in practice aligns with WHO PVS
160 guidelines. The results of this review will help establish an evidence base to inform future PVS policies and programs.

161 The GPELF and its regional sub-programs have been recognised as successful public health interventions for the elimination
162 of LF in 21 countries and the prevention of more than 3 million DALYs. However, as more countries achieve elimination of
163 LF as a public health problem, there is a pressing need to ensure that any resurgence is detected in a timely way through the
164 implementation of appropriate PVS. Without PVS, there remains the potential for LF recrudescence to go undetected, leading
165 to further costly and preventable illness.

166 Each LF-endemic country has a unique epidemiological profile, opportunities, and constraints for the implementation of PVS
167 which must be considered when designing national PVS strategies. As such, gathering evidence to inform on the selection
168 and tailoring of PVS strategies is key for the ongoing success of LF elimination efforts. Understanding which PVS strategies
169 have been employed and what the experience of implementation has been will provide valuable insights that others may draw
170 on when designing their own PVS programs. Further, generating evidence as to whether what has been effective in practice
171 aligns with existing guidelines will help tailor future recommendations.

172 Due to the diverse contexts in which PVS takes place, we expect there will be significant heterogeneity in the included
173 studies. Additionally, without formal publication requirements, it is possible that countries conducting PVS may not publish
174 data describing some or all of their activities, though we anticipate that some of these findings will be captured in the grey
175 literature. Further, we acknowledge that valuable experiences and lessons learned will not have been captured in the scientific
176 or grey literature and hence missed by this review. Recognition of this limitation opens opportunities for future research.

177 This review will map and evaluate the quality of the body of evidence on PVS of LF, which, to our knowledge, has not yet
178 been conducted. Through collating and analysing literature on what strategies have been employed by previously endemic

179 countries, this review will provide evidence on the operational feasibility of various PVS strategies, including those that will
180 be recommended by WHO. Additionally, the review will identify knowledge gaps that require further research. We expect
181 that our findings will assist and guide the design of future PVS strategies.


182 **References**

- 183 1. Ichimori K, Graves PM. Overview of PacELF-the Pacific Programme for the Elimination of Lymphatic Filariasis.
184 Trop Med Health. 2017;45:34. Epub 20171101. doi: 10.1186/s41182-017-0075-4. PubMed PMID: 29118654; PubMed
185 Central PMCID: PMCPMC5664808.
- 186 2. Centers for Disease Control and Prevention. Lymphatic Filariasis 2019 [cited 2024 17/10/24]. Available from:
187 https://www.cdc.gov/dpdx/lymphaticfilariasis/modules/W_bancrofti_LifeCycle_lg.jpg.
- 188 3. World Health Organization. Lymphatic filariasis (Elephantiasis) 2024 [cited 3/12/2024]. Available from:
189 <https://www.who.int/data/gho/data/themes/topics/lymphatic-filariasis>.
- 190 4. World Health Organization. Regional Office for South-East A. FAQs: Frequently asked questions on Lymphatic
191 Filariasis (elephantiasis). New Delhi: WHO Regional Office for South-East Asia; 2014 2014.
- 192 5. Hofstraat K, van Brakel WH. Social stigma towards neglected tropical diseases: a systematic review. Int Health.
193 2016;8 Suppl 1:i53-70. doi: 10.1093/inthealth/ihv071. PubMed PMID: 26940310.
- 194 6. Mathew CG, Bettis AA, Chu BK, English M, Ottesen EA, Bradley MH, Turner HC. The Health and Economic
195 Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs. Clin Infect Dis. 2020;70(12):2561-7. doi:
196 10.1093/cid/ciz671. PubMed PMID: 31343064; PubMed Central PMCID: PMCPMC7286370.
- 197 7. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and
198 territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204-
199 22. doi: 10.1016/S0140-6736(20)30925-9. PubMed PMID: 33069326; PubMed Central PMCID: PMCPMC7567026.
- 200 8. World Health Organization. Global Programme to Eliminate Lymphatic Filariasis 2024 [18/09/24]. Available from:
201 [https://www.who.int/teams/control-of-neglected-tropical-diseases/lymphatic-filariasis/global-programme-to-eliminate-](https://www.who.int/teams/control-of-neglected-tropical-diseases/lymphatic-filariasis/global-programme-to-eliminate-lymphatic-filariasis)
202 [lymphatic-filariasis](https://www.who.int/teams/control-of-neglected-tropical-diseases/lymphatic-filariasis/global-programme-to-eliminate-lymphatic-filariasis).
- 203 9. Ottesen EA, Hooper PJ, Bradley M, Biswas G. The global programme to eliminate lymphatic filariasis: health
204 impact after 8 years. PLoS Negl Trop Dis. 2008;2(10):e317. Epub 20081008. doi: 10.1371/journal.pntd.0000317. PubMed
205 PMID: 18841205; PubMed Central PMCID: PMCPMC2556399.

- 206 10. Kapa DR, Mohamed AJ. Progress and impact of 20 years of a lymphatic filariasis elimination programme in South-
207 East Asia. *International Health*. 2021;13:S17-S21. doi: 10.1093/inthealth/ihaa056.
- 208 11. Deribe K, Bakajika DK, Zoure HMG, Gyapong JO, Molyneux DH, Rebollo MP. African regional progress and
209 status of the programme to eliminate lymphatic filariasis: 2000-2020. *International Health*. 2021;13:S22-S7. doi:
210 10.1093/inthealth/ihaa058.
- 211 12. Collyer BS, Irvine MA, Hollingsworth TD, Bradley M, Anderson RM. Defining a prevalence level to describe the
212 elimination of Lymphatic Filariasis (LF) transmission and designing monitoring & evaluating (M&E) programmes post the
213 cessation of mass drug administration (MDA). *PLoS Negl Trop Dis*. 2020;14(10):e0008644. Epub 20201012. doi:
214 10.1371/journal.pntd.0008644. PubMed PMID: 33044958; PubMed Central PMCID: PMC7549789.
- 215 13. World Health Organization. Validation of elimination of lymphatic filariasis as a public health problem. Geneva:
216 2017.
- 217 14. World Health Organisation. Monitoring and epidemiological assessment of mass drug administration in the global
218 programme to eliminate lymphatic filariasis: a manual for national elimination programmes. 2011.
- 219 15. Meetham P, Kumler R, Gopinath D, Yongchaitrakul S, Tootong T, Rojanapanus S, Padungtod C. Five years of
220 post-validation surveillance of lymphatic filariasis in Thailand. *Infectious Diseases of Poverty*. 2023;12(1):1-18. doi:
221 10.1186/S40249-023-01158-0/TABLES/10.
- 222 16. Craig A, Sanikullah K. Post-validation surveillance for lymphatic filariasis. COR-NTD Meeting for the Pacific
223 Islands 2024 Breakout Reports 2024.
- 224 17. Rahman MA, Yahathugoda TC, Tojo B, Premaratne P, Nagaoka F, Takagi H, et al. A surveillance system for
225 lymphatic filariasis after its elimination in Sri Lanka. *Parasitology International*. 2019;68(1):73-8. doi:
226 10.1016/j.parint.2018.10.003.
- 227 18. Lawford H, Tukia O, Takai J, Sheridan SL, Ward S, Jian H, et al. Localised Transmission of Lymphatic Filariasis in
228 Tonga Seven Years after Validation of Elimination as a Public Health Problem. *Preprints with The Lancet*. 2024. doi:
229 <http://dx.doi.org/10.2139/ssrn.5028551>

- 230 19. World Health Organisation. Ending the neglect to attain the Sustainable Development Goals: A road map for
231 neglected tropical diseases 2021–2030. 2020.
- 232 20. World Health Organisation. Global programme to eliminate lymphatic filariasis: Progress report on mass drug
233 administration in 2007. 2007 Contract No.: WER No 37/38, 2008, 83, 33–341.
- 234 21. Elo S, Kyngas H. The qualitative content analysis process. *J Adv Nurs*. 2008;62(1):107-15. doi: 10.1111/j.1365-
235 2648.2007.04569.x. PubMed PMID: 18352969.
- 236 22. Joanna Briggs Institute. Critical Appraisal Checklist for Cross Sectional Studies 2017. Available from:
237 https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-
238 [Checklist_for_Analytical_Cross_Sectional_Studies2017_0.pdf](https://jbi.global/sites/default/files/2019-05/JBI_Critical_Appraisal-Checklist_for_Analytical_Cross_Sectional_Studies2017_0.pdf)

Distribution of lymphatic filariasis and status of preventive chemotherapy (PC) in endemic countries, 2024



The boundaries and names shown and the designations used on this map do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. © WHO 2024. All rights reserved

Data Source: World Health Organization
Map Production: Control of Neglected Tropical Diseases (NTD)
World Health Organization



Figure 1